Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JGC Takes Over CROBusiness from Tokyo CRO
October 11, 2010
- EML4-ALK Mutations Seen in 5.2% of Japanese Lung Cancer Patients
October 11, 2010
- Nippon Kayaku's NK105 Found Effective for Stomach Cancer in PII
October 11, 2010
- Takeda to Construct New Formulation Plant in Hikari
October 4, 2010
- Banyu Warned about Payment to Doctors Attending Januvia Seminars
October 4, 2010
- Canagliflozin Significantly Reduces HbA1c, Weight in PIIb
October 4, 2010
- Takeda Launches Dexilant in Canada
October 4, 2010
- EMA Recommends Suspension, US FDA Restricts Access to Avandia
October 4, 2010
- Diabetes Increasing in Asia: EASD President Prof. Smith
October 4, 2010
- MTPC Transfers 3 Long-Listed Products to Its Subsidiary
October 4, 2010
- Ono Applies for the Antiemetic Fosaprepitant
October 4, 2010
- EASD Welcomes GL Proposed by EMA
October 4, 2010
- BMS to Acquire ZymoGenetics through Tender Offer
October 4, 2010
- Dabigatran Receives Recommendation by FDA Committee: BI
October 4, 2010
- Otsuka to Codevelop OPA-6566 for Glaucoma with Acucela
October 4, 2010
- Daiichi Sankyo Completes Tender Offer for Zenotech Lab
October 4, 2010
- FDA Accepts NDA for Aricept Transdermal Patch: Eisai, Teikoku Seiyaku
October 4, 2010
- Takara Bio to Obtain Anticancer Agent from M's Science
October 4, 2010
- Japan's Own COI Disclosure System Necessary: Mr Hirai
October 4, 2010
- FDA Advisory Committee Not Recommend Approval for Lorcaserin: Eisai
October 4, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…